New peer-reviewed article explores buprenorphine’s potential as a novel harm reduction approach
FOR IMMEDIATE RELEASE June 2, 2026 CALGARY — A new peer-reviewed article published in Pharmaceuticals and co-authored by CoRE’s Chief Scientific Officer, Dr. Nathaniel Day, suggests buprenorphine, a medication commonly used to treat opioid use disorder, may also reduce the risk of fentanyl-induced respiratory depression, the primary cause of fatal opioid overdoses. The paper examines … Continued